LUC7L Inhibitors
LUC7L inhibitors are a class of chemical compounds that specifically target the LUC7L protein, a component involved in the regulation of RNA splicing, which is crucial for processing pre-mRNA into mature mRNA. LUC7L belongs to the LUC7-like family of proteins and plays a significant role in spliceosome assembly, particularly in the selection of 5' splice sites during the splicing process. Splicing is essential for gene expression as it allows the removal of introns from pre-mRNA and the joining of exons, ensuring that the correct coding sequences are assembled for protein translation. Inhibitors of LUC7L disrupt its function in splice site recognition, leading to alterations in RNA splicing fidelity and the generation of improperly spliced mRNA.
The mechanism of action for LUC7L inhibitors typically involves binding to functional domains of the LUC7L protein, preventing it from interacting with other spliceosomal components or recognizing the correct 5' splice sites. By inhibiting LUC7L activity, these compounds interfere with the precise regulation of pre-mRNA splicing, which can result in the production of aberrant mRNA transcripts and subsequent defects in protein synthesis. LUC7L inhibitors are valuable tools for studying the intricate mechanisms of RNA splicing and how specific proteins, such as LUC7L, contribute to spliceosome function and the regulation of gene expression. Researchers use these inhibitors to explore the broader impacts of splicing defects on cellular processes, including how mis-splicing can affect cell differentiation, growth, and overall gene expression regulation at the post-transcriptional level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytidine analog may downregulate LUC7L by incorporating into genomic DNA, leading to demethylation and disruption of transcriptional regulation of the LUC7L gene. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine could decrease LUC7L expression by inducing DNA hypomethylation, thereby altering the epigenetic marks that control the transcription of the LUC7L gene. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid may suppress LUC7L by inhibiting histone deacetylase activity, which can result in chromatin remodeling and reduction of LUC7L gene transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A might downregulate LUC7L through histone deacetylase inhibition, leading to a compact chromatin state that is less permissive for the transcription of the LUC7L gene. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
By inhibiting histone deacetylation, Romidepsin could reduce LUC7L expression, effectively silencing gene transcription due to chromatin condensation. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A is known to bind to GC-rich sequences in DNA, which may repress LUC7L transcription by blocking the binding of transcriptional activators or the assembly of the transcriptional machinery. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D could inhibit LUC7L expression by intercalating into DNA, which would obstruct the progression of RNA polymerase and halt the transcription process of the LUC7L gene. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin targets the mTOR pathway and could suppress LUC7L synthesis by inhibiting downstream signaling pathways that control ribosomal biogenesis and mRNA translation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may downregulate LUC7L by interfering with transcriptional initiation, possibly by inhibiting the activity of RNA polymerase II or transcription factors necessary for LUC7L gene expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine could reduce LUC7L expression by disrupting endosomal acidification and lysosomal function, which may alter the cellular environment and transcription factor activities related to the LUC7L gene. | ||||||